ATE304375T1 - Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren - Google Patents
Cd40 bindende antikörper und ctl peptide zur behandlung von tumorenInfo
- Publication number
- ATE304375T1 ATE304375T1 AT99937841T AT99937841T ATE304375T1 AT E304375 T1 ATE304375 T1 AT E304375T1 AT 99937841 T AT99937841 T AT 99937841T AT 99937841 T AT99937841 T AT 99937841T AT E304375 T1 ATE304375 T1 AT E304375T1
- Authority
- AT
- Austria
- Prior art keywords
- treating tumors
- composition
- peptides
- ctl
- fab
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 101150013553 CD40 gene Proteins 0.000 title abstract 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8662598P | 1998-05-23 | 1998-05-23 | |
| PCT/US1999/011419 WO1999061065A1 (en) | 1998-05-23 | 1999-05-21 | Cd40 binding molecules and ctl peptides for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304375T1 true ATE304375T1 (de) | 2005-09-15 |
Family
ID=22199819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937841T ATE304375T1 (de) | 1998-05-23 | 1999-05-21 | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7563445B2 (de) |
| EP (2) | EP1616579B1 (de) |
| JP (1) | JP4927254B2 (de) |
| CN (2) | CN1212155C (de) |
| AT (1) | ATE304375T1 (de) |
| AU (1) | AU765822B2 (de) |
| DE (2) | DE69927262T2 (de) |
| DK (2) | DK1082141T3 (de) |
| ES (2) | ES2330017T3 (de) |
| NZ (1) | NZ508831A (de) |
| WO (1) | WO1999061065A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE304375T1 (de) * | 1998-05-23 | 2005-09-15 | Univ Leiden Medical Ct | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren |
| US6680176B2 (en) | 1999-05-17 | 2004-01-20 | The United States Of America, As Represented By The Department Of Health And Human Services | Identification of candidate ligands which modulate antigen presenting cells |
| US20030118588A1 (en) * | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU6677000A (en) * | 1999-08-27 | 2001-03-26 | University Health Network | Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen |
| EP1975182A1 (de) * | 2000-02-01 | 2008-10-01 | PanGenetics B.V. | CD40-bindende und APC-aktivierende Moleküle |
| WO2001064248A1 (en) * | 2000-03-02 | 2001-09-07 | Medimmune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
| WO2006113209A1 (en) * | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| RU2407544C2 (ru) | 2005-05-26 | 2010-12-27 | Сиэтл Дженетикс, Инк. | Гуманизированные анти-cd40-антитела и способы их применения |
| EP2019857B1 (de) | 2006-05-03 | 2016-09-28 | The Regents of the University of Colorado, a body corporate | Synergistische hilfsstoffkombination aus cd40-agonist-antikörper/typ-1-interferon, diese enthaltende konjugate und ihre verwendung als therapeutika zur verstärkung der zellimmunität |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| GB0703976D0 (en) * | 2007-03-02 | 2007-04-11 | Adjuvantix Ltd | Liposome preparation |
| CA2996732C (en) | 2007-03-26 | 2020-10-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Prame derived peptides and immunogenic compositions comprising these |
| CA3167595A1 (en) | 2007-05-31 | 2008-12-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines |
| CA2688589A1 (en) | 2007-05-31 | 2008-12-31 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Intradermal hpv peptide vaccination |
| ES2406077T3 (es) | 2007-05-31 | 2013-06-05 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacuna de péptido p53 |
| AU2009286247A1 (en) * | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| GB2478283A (en) * | 2010-03-01 | 2011-09-07 | Nissan Motor Mfg | Vehicle occupant restraint control apparatus |
| EP2608802B1 (de) | 2010-08-27 | 2017-02-22 | Pantarhei Bioscience B.V. | Immuntherapeutisches verfahren zur behandlung von prostatakrebs |
| EP2471543A1 (de) | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Toleranzinduktion oder Immunsuppression zur Verhinderung von insbesondere Transplantat-Wirt-Reaktion (GvHD) durch kurzzeitige Vorinkubation von transplantierten Zellsuspensionen, Geweben oder Organen, die mit Liganden zu Zelloberflächenmolekülen beschichtet sind |
| WO2013006050A1 (en) | 2011-07-06 | 2013-01-10 | Isa Pharmaceuticals B.V. | Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA) |
| EP2687849A1 (de) | 2012-07-20 | 2014-01-22 | ISA Pharmaceuticals B.V | Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung |
| WO2015187009A1 (en) | 2014-06-02 | 2015-12-10 | Isa Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
| WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| KR20230030032A (ko) | 2016-06-20 | 2023-03-03 | 아이에스에이 파마슈티컬즈 비.브이. | 펩타이드 백신의 제형 |
| AR111625A1 (es) | 2017-04-27 | 2019-07-31 | Juno Therapeutics Gmbh | Reactivos de partículas oligoméricas y métodos de uso de los mismos |
| US20210317165A1 (en) | 2018-09-03 | 2021-10-14 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
| BR112021008133A2 (pt) | 2018-10-31 | 2021-10-05 | Juno Therapeutics Gmbh | Métodos para seleção e estimulação de células e aparelhos para os mesmos |
| BR112021008738A2 (pt) | 2018-11-06 | 2021-11-03 | Juno Therapeutics Inc | Processo para produzir células t geneticamente construídas |
| KR20220101641A (ko) | 2019-10-30 | 2022-07-19 | 주노 테라퓨틱스 게엠베하 | 세포 선택 및/또는 자극 장치 및 사용 방법 |
| WO2021156404A2 (en) | 2020-02-07 | 2021-08-12 | Isa Pharmaceuticals | Treatment of hpv-related diseases |
| CN115835873A (zh) | 2020-05-13 | 2023-03-21 | 朱诺治疗学股份有限公司 | 用于产生表达重组受体的供体分批细胞的方法 |
| WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| PT724456E (pt) * | 1993-10-01 | 2004-04-30 | Immunex Corp | Anticorpos contra cd4 |
| KR19980702490A (ko) * | 1995-03-01 | 1998-07-15 | 스티븐 엘. 말라스카 | 면역 반응의 자극 방법 |
| JP4108126B2 (ja) * | 1996-04-26 | 2008-06-25 | リュクスウニヴェルシテート テ レイデン | Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| ATE304375T1 (de) * | 1998-05-23 | 2005-09-15 | Univ Leiden Medical Ct | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren |
-
1999
- 1999-05-21 AT AT99937841T patent/ATE304375T1/de active
- 1999-05-21 DE DE69927262T patent/DE69927262T2/de not_active Expired - Lifetime
- 1999-05-21 CN CNB998076694A patent/CN1212155C/zh not_active Expired - Fee Related
- 1999-05-21 CN CNA2005100752729A patent/CN1762492A/zh active Pending
- 1999-05-21 WO PCT/US1999/011419 patent/WO1999061065A1/en active IP Right Grant
- 1999-05-21 AU AU43112/99A patent/AU765822B2/en not_active Ceased
- 1999-05-21 NZ NZ508831A patent/NZ508831A/en not_active IP Right Cessation
- 1999-05-21 ES ES05107101T patent/ES2330017T3/es not_active Expired - Lifetime
- 1999-05-21 DK DK99937841T patent/DK1082141T3/da active
- 1999-05-21 EP EP05107101A patent/EP1616579B1/de not_active Expired - Lifetime
- 1999-05-21 JP JP2000550524A patent/JP4927254B2/ja not_active Expired - Fee Related
- 1999-05-21 DK DK05107101T patent/DK1616579T3/da active
- 1999-05-21 EP EP99937841A patent/EP1082141B1/de not_active Expired - Lifetime
- 1999-05-21 DE DE69941165T patent/DE69941165D1/de not_active Expired - Lifetime
- 1999-05-21 ES ES99937841T patent/ES2249907T3/es not_active Expired - Lifetime
-
2002
- 2002-08-26 US US10/227,789 patent/US7563445B2/en not_active Expired - Fee Related
-
2009
- 2009-07-17 US US12/505,022 patent/US20090285814A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1616579B1 (de) | 2009-07-22 |
| AU4311299A (en) | 1999-12-13 |
| DE69941165D1 (de) | 2009-09-03 |
| EP1616579A1 (de) | 2006-01-18 |
| CN1346284A (zh) | 2002-04-24 |
| DE69927262D1 (de) | 2006-01-26 |
| EP1082141A1 (de) | 2001-03-14 |
| ES2330017T3 (es) | 2009-12-03 |
| ES2249907T3 (es) | 2006-04-01 |
| US20030022860A1 (en) | 2003-01-30 |
| AU765822B2 (en) | 2003-10-02 |
| JP4927254B2 (ja) | 2012-05-09 |
| EP1082141B1 (de) | 2005-09-14 |
| JP2002528383A (ja) | 2002-09-03 |
| DK1082141T3 (da) | 2005-12-05 |
| NZ508831A (en) | 2004-08-27 |
| CN1212155C (zh) | 2005-07-27 |
| CN1762492A (zh) | 2006-04-26 |
| US20090285814A1 (en) | 2009-11-19 |
| US7563445B2 (en) | 2009-07-21 |
| WO1999061065A1 (en) | 1999-12-02 |
| DE69927262T2 (de) | 2006-04-27 |
| EP1082141A4 (de) | 2002-08-07 |
| DK1616579T3 (da) | 2009-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304375T1 (de) | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren | |
| ATE303161T1 (de) | Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung | |
| DE69429925D1 (de) | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID | |
| ATE483733T1 (de) | Hochaffine humane antikörper gegen tumorantigene | |
| CO5580797A2 (es) | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos | |
| ATE549347T1 (de) | Gene von säugetiere, und damit verbundene reagentien, methoden | |
| HK1091499A1 (en) | Methods for preventing and treating alzheimers disease (ad) (ad) | |
| ATE283916T1 (de) | Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen | |
| DK0724456T3 (da) | CD40-Antistoffer | |
| ATE478944T1 (de) | Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität | |
| ATE415423T1 (de) | Immunisierungstherapie zur behandlung von atherosklerose | |
| DE59309458D1 (de) | Synthetische Peptide, Antikörper dagegen und ihre Verwendung | |
| DE69532588D1 (de) | Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen | |
| GR3018371T3 (en) | Method for identifying or determining proteins and applications therefor. | |
| WO1995021922A3 (en) | Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use | |
| DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
| DK0937153T3 (da) | Humane monoklonale antistoffer, der er specifikke for hepatitis C-virus (HCV) E2 antigen | |
| ATE94880T1 (de) | Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung. | |
| ATE285418T1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
| DE59508137D1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
| DE60231475D1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
| Chaiken et al. | A solid phase synthetic study of structure-function relationships in the amino-terminal region of staphylococcal nuclease | |
| DE69617255T2 (de) | Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung | |
| WO2001066745A3 (en) | Presenilin/crk binding polypeptides (pcbp) and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1082141 Country of ref document: EP |